D-1127-2017 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-1127-2017 was initiated by Lupin Pharmaceuticals Inc. on May 2, 2017 and is designated Class III. Reason for recall: CGMP Deviations The recall status is terminated (terminated Mar 28, 2018). Affected quantity: 12,888 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 13, 2017
Initiation Date
May 2, 2017
Termination Date
Mar 28, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,888 bottles

Product description

Famotidine for Oral Suspension USP, 40 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Goa 403 722 INDIA, NDC 68180-150-01

Reason for recall

CGMP Deviations

Distribution pattern

Nationwide in the USA

Code information

Lot #: G606950, Exp 07/18

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1127-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1127-2017. Report a data issue: hello@regdatalab.com.